Ultra-LEAF™ Purified anti-mouse CXCL9 (MIG) Antibody, CXCL9, A16072G,BioLegend,942603

CXCL9 is an inflammatory chemokine initially identified by differential screening of a cDNA library from limphokine-activated macrophages. CXCL9 is a CXC chemokine and member of the non-ELR (lacking a Glu-Leu-Arg motif in the N-terminal region) CXC chemokine family. CXCL9 shares the CXCR3 receptor with CXCL10 and CXCL11, and these ligands differ in their receptor-binding and activating properties; CXCL11 is more potent than CXCL10 and CXCL10 is more potent than CXCL9. CXCL9 plays a key role in leukocyte trafficking, acting on activated CD4+ Th1 cells, CD8+ T cells, IL-2 activated T lymphocytes, and NK cells. In addition, CXCL9 enhances T lymphocyte function in alloimmune response; CXCL9 induces T cells proliferation and cytokine production in an experimental model of cardiac allograft vasculopathy. Also, CXCL9 has angiostatic activity. Additionally, it has been hypothesized that CXCL9, CXCL10, and CXCL11 contribute to host defense against inhalational anthrax in a murine model of infection. CXCL9 is induced by cytokines, particularly IFN-γ during infection, injury, or immunoinflammatory responses, and it can be inactivated by CD26/dipeptidil peptidase IV after truncation by this protease.